Swissmedic Approves Zambon and Newron Therapy against Parkinson’s

16/11/2015 - 2 minutes

Italian Pharma Newron and its partner Zambon (from Milan) have been granted a license by Swissmedic (the regulatory agency in Switzerland) for Xadago, a new combo ‘add-on’ therapy for Parkinson’s Disease.

Zambon_newronZambon, is a Pharmaceutical Company with a strong commitment in central nervous system (CNS) diseases. Its partner, Newron Pharmaceuticals, is a research and development biotech from northern Italy which is focused on novel CNS and pain therapies.

Xadago (Safinamide) is the flagship drug in Newron’s pipeline, and is actually the first New Chemical Entity (NCE) in 10 years to receive a Marketing Authorization from the EU Commission for the treatment of Parkinson’s disease.

Xadago will be now be used as add-on therapy to levodopa (L-dopa), alone or in combination with other therapies for patients with Parkinson’s disease, who have mid-to late-stage and motor fluctuations. The approval in Switzerland was preceded by the marketing authorization throughout the European Union by the Commission of the EU,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member